Palvella Therapeutics, Inc. (PVLA) Earnings History
Net Loss6 years of earnings data (2020–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Palvella Therapeutics, Inc. (PVLA) Earnings Overview
As of June 28, 2026, Palvella Therapeutics, Inc. (PVLA) reported trailing twelve-month net income of -$49M, reflecting +52.6% year-over-year growth. The company earned $-3.77 per diluted share over the past four quarters.
Looking at the long-term picture, PVLA's historical earnings data spans multiple years. The company achieved its highest annual net income of $19M in fiscal 2023.
Palvella Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NKTR (-$158M net income, -297.1% margin), PRAX (-$327M net income), IMVT (-$506M net income), PVLA has comparable earnings metrics. Compare PVLA vs NKTR →
PVLA Earnings vs Peers
Earnings metrics vs comparable public companies
PVLA Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$42M | -139.3% | -$39M | $-3.71 | - | - |
| 2024 | -$17M | -193.3% | -$14M | $-7.83 | - | - |
| 2023 | $19M | +156.2% | -$12M | $14.74 | - | - |
| 2022 | -$33M | +27.2% | -$43M | $-29.61 | -128.5% | -167.8% |
| 2021 | -$46M | -22.9% | -$52M | $-56.69 | -145.6% | -165.0% |
| 2020 | -$37M | - | -$34M | $-54.67 | -127.0% | -115.7% |
Download Data
Export PVLA earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PVLA — Frequently Asked Questions
Quick answers to the most common questions about buying PVLA stock.
What is PVLA earnings per share (EPS)?
PVLA trailing twelve-month (TTM) diluted EPS is $-3.77, reflecting +52.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2020 to 2025 is available in the table on this page.
What is Palvella Therapeutics, Inc.'s net income?
Palvella Therapeutics, Inc. (PVLA) trailing twelve-month net income is $-49M as of 2025. Earnings grew +52.6% year-over-year.
Is PVLA profitable?
PVLA is not currently profitable on a TTM basis, reporting a net loss of $-49M. Net margin is N/A. Investors should monitor for a return to profitability.
What is PVLA's earnings growth rate?
PVLA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2020 to 2025.
What are PVLA's profit margins?
Palvella Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -92.1%.
Is PVLA growing earnings?
Yes, PVLA earnings are accelerating — EPS growth of +52.6% exceeds the 5-year CAGR of N/A. TTM net income reached $-49M. Earnings momentum is strengthening.
What was PVLA's best earnings year?
Palvella Therapeutics, Inc.'s highest annual net income on record is $19M, achieved in fiscal year 2023. Earnings history on this page spans 2020 to 2025 and includes all annual and quarterly figures.
What were PVLA's earnings last quarter?
PVLA's most recent reported quarter was Q1 2026. Net income was $-16M with diluted EPS of $-1.20. For a full breakdown of all quarters, see the quarterly earnings table on this page.